Literature DB >> 2468325

Virus strain specificity of challenge immunity to coronavirus.

S W Barthold1, A L Smith.   

Abstract

The resistance of immunized mice to challenge with the same or a different strain of mouse hepatitis virus (MHV) was examined as a model of challenge immunity to coronavirus infection. Genetically susceptible BALB/cByJ mice were given an intranasal immunizing infection of respiratory-type MHV-JHM, MHV-S, or enterotropic MHV-Y. Control mice were sham-immunized with sterile tissue culture fluid. Recovered mice were challenged intranasally with MHV-JHM, MHV-S or sterile tissue culture fluid at 30 days after immunization. Resistance to challenge inoculation was evaluated in groups of mice at 4 and 30 days after challenge. At 4 days, the prevalence of MHV lesions in nose and liver was tabulated and MHV titers in liver were determined. At 30 days, the prevalence of residual brainstem spongiform lesions was tabulated and serum antibody to MHV-JHM and MVH-S was quantified by enzyme immunoassay. Mice immunized with MHV-JHM or MHV-S resisted challenge with the MHV homotype, but MHV-S-immunized mice were fully susceptible to challenge with MVH-JHM. Mice immunized with enterotropic MHV-Y were only partially protected against challenge with antigenically related, but biologically different MHV-S. Serum antibody responses to MHV supported these observations. These data indicate that challenge immunity to coronaviruses is strong, but highly virus strain-specific.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2468325      PMCID: PMC7086909          DOI: 10.1007/bf01315542

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  23 in total

1.  Host age and genotypic effects on enterotropic mouse hepatitis virus infection.

Authors:  S W Barthold
Journal:  Lab Anim Sci       Date:  1987-02

2.  Resistance to highly virulent mouse hepatitis virus acquired by mice after low-virulence infection: enhanced antiviral activity of macrophages.

Authors:  F Taguchi; A Yamada; K Fujiwara
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441

Review 3.  The biology and pathogenesis of coronaviruses.

Authors:  H Wege; S Siddell; V ter Meulen
Journal:  Curr Top Microbiol Immunol       Date:  1982       Impact factor: 4.291

4.  Epizootic coronaviral typhlocolitis in suckling mice.

Authors:  S W Barthold; A L Smith; P F Lord; P N Bhatt; R O Jacoby; A J Main
Journal:  Lab Anim Sci       Date:  1982-08

5.  Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence.

Authors:  R G Dalziel; P W Lampert; P J Talbot; M J Buchmeier
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

6.  New strain of mouse hepatitis virus as the cause of lethal enteritis in infant mice.

Authors:  J C Hierholzer; J R Broderson; F A Murphy
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

7.  Murine hepatitis virus-4 (strain JHM)-induced neurologic disease is modulated in vivo by monoclonal antibody.

Authors:  M J Buchmeier; H A Lewicki; P J Talbot; R L Knobler
Journal:  Virology       Date:  1984-01-30       Impact factor: 3.616

8.  Intranasally administered alpha/beta interferon prevents extension of mouse hepatitis virus, strain JHM, into the brains of BALB/cByJ mice.

Authors:  A L Smith; S W Barthold; D S Beck
Journal:  Antiviral Res       Date:  1987-12       Impact factor: 5.970

9.  Mouse hepatitis virus S in weanling Swiss mice following intranasal inoculation.

Authors:  S W Barthold; A L Smith
Journal:  Lab Anim Sci       Date:  1983-08

10.  Mouse hepatitis virus strain--related patterns of tissue tropism in suckling mice.

Authors:  S W Barthold; A L Smith
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

View more
  11 in total

1.  Duration of challenge immunity to coronavirus JHM in mice.

Authors:  S W Barthold; A L Smith
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

2.  Coronavirus infection in the laboratory rat: immunization trials using attenuated virus replicated in L-2 cells.

Authors:  D H Percy; R A Scott
Journal:  Can J Vet Res       Date:  1991-01       Impact factor: 1.310

3.  Responses of mice to murine coronavirus immunization.

Authors:  A L Smith; M S de Souza; D Finzi; S W Barthold
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens.

Authors:  J Ignjatovic; L Galli
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

5.  Binding of the coronavirus mouse hepatitis virus A59 to its receptor expressed from a recombinant vaccinia virus depends on posttranslational processing of the receptor glycoprotein.

Authors:  M N Pensiero; G S Dveksler; C B Cardellichio; G S Jiang; P E Elia; C W Dieffenbach; K V Holmes
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

6.  Coronavirus infections in the laboratory rat: degree of cross protection following immunization with a heterologous strain.

Authors:  C G Bihun; D H Percy
Journal:  Can J Vet Res       Date:  1994-07       Impact factor: 1.310

Review 7.  All in the family: A comparative look at coronaviruses.

Authors:  John Ellis
Journal:  Can Vet J       Date:  2021-08       Impact factor: 1.008

Review 8.  Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2.

Authors:  Robert W Körner; Mohamed Majjouti; Miguel A Alejandre Alcazar; Esther Mahabir
Journal:  Viruses       Date:  2020-08-12       Impact factor: 5.048

9.  Antibody responsiveness during immunization and challenge of genetically modified antibody responder mice with murine hepatitis virus 3.

Authors:  Ruth C Vassão; Cleide A Consales; Osvaldo A Sant'Anna; Carlos A Pereira
Journal:  Immunobiology       Date:  2003       Impact factor: 3.144

10.  Sequence analysis of the nucleoprotein genes of three enterotropic strains of murine coronavirus.

Authors:  F R Homberger
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.